Adverse effect: fatigue · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Fatigue ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
Intervention not reported
All‐cause mortality · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Relapsec · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
The intervention probably leads to higher relapsec (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC >…
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 5‐ to 6‐year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 12 year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: radiotherapy Comparison: no adjuvant treatment Outcome: neurocognitive impairment at 2 year · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: radiotherapy Comparison: no adjuvant treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 2 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: high‐dose radiotherapy Comparison: low‐dose radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
It is very uncertain whether the intervention changes intervention: high‐dose radiotherapy Comparison: low‐dose… (very low certainty).
1 finding from 1 review
Intervention not reported
Intervention: chemoradiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 3 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: chemoradiotherapy Comparison: radiotherapy Outcome:… (low certainty).
1 finding from 1 review
Intervention not reported
Intervention: stereotactic conformal radiotherapy Comparison: radiotherapy Outcome: neurocognitive impairment at 5 years after treatment · people with glioma surviving at least two years
The intervention showed no clear difference in intervention: stereotactic conformal radiotherapy Comparison:… (low certainty).
1 finding from 1 review
Overall survival · advanced pancreatic cancer
Anti‐cancer therapy showed no clear difference in overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus topoisomerase inhibitor · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus taxane · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus other agent(s) · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival · advanced pancreatic cancer
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
1 finding from 1 review